Ingestible Wirelessly Powered Electronics Devices

April 30, 2017 Vijay Soni 0

Ingestible Wirelessly Powered Electronics Devices By: Anne Trafton | MIT News Office April 30, 2017 Researchers at MIT, Brigham and Women’s Hospital, and the Charles Stark Draper Laboratory have devised a way to wirelessly power small electronic devices that can linger in the digestive tract indefinitely after being swallowed. Such [..]

FDA Approves Brineura™ As The First Treatment of CLN2 Disease

April 27, 2017 Vijay Soni 0

FDA Approves Brineura™ As The First Treatment of CLN2 Disease  SOURCE: BioMarin Pharmaceutical Inc. Apr 27, 2017 BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) approved Brineura™ (cerliponase alfa) to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and [..]

Innovative Entrepreneurial Intentions can Be Cultivated By College

April 27, 2017 Vijay Soni 0

Innovative Entrepreneurial Intentions can Be Cultivated By College Innovative entrepreneurial intentions – or the aim to create new products and bring them to market, rather than replicating existing products – are boosted by college experiences, according to research by NYU’s Steinhardt School of Culture, Education, and Human Development. The multi-country [..]

Stronger Polymers: By A Simple & New Method

April 24, 2017 Vijay Soni 0

Stronger Polymers: By A Simple & New Method  Source: Anne Trafton | MIT News Office April 24, 2017 Plastic, rubber, and many other useful materials are made of polymers — long chains arranged in a cross-linked network. At the molecular level, these polymer networks contain structural flaws that weaken them. [..]

Novel Lens For Super-Resolution Imaging

April 21, 2017 Vijay Soni 0

Novel Lens For Super-Resolution Imaging Source: NUS News April 21, 2017 The optical microscope is a critical equipment for scientific research and failure inspection in high precision industries. However, for centuries, the imaging resolution of microscopes is fundamentally limited by the diffraction limit of light. Existing efforts to break this [..]

FDA Approved Neurocrine’s INGREZZA TM As First and Only Treatment for Tardive Dyskinesia (TD)

April 19, 2017 Vijay Soni 0

FDA Approved Neurocrine’s INGREZZATM As First and Only Treatment for Tardive Dyskinesia (TD) April 19, 2017 Source: Neurocrine Biosciences, Inc NEWS Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced that the U.S. Food and Drug Administration (FDA) has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). INGREZZA, a novel, selective [..]

Breakthrough In Gene-Editing

April 17, 2017 Vijay Soni 0

Breakthrough In Gene-Editing  Source: SNU Media April 17, 2017 Professor Kim Jin-Soo and training researcher Kim Daesik, both of the Department of Chemistry, were part of a research team at the Center for Genomic Engineering, within the Institute for Basic Science (IBS), that proved that a newly developed gene editing [..]

FDA Approves Gilead’s Two New Hepatitis C Drugs For Pediatric Patients

April 15, 2017 Vijay Soni 0

FDA Approves Gilead’s Two New Hepatitis C Drugs For Pediatric Patients Source: BUSINESS WIRE |  April, 15 2017 Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has approved supplemental indications for Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) tablets and Sovaldi® (sofosbuvir 400 mg) tablets [..]

No More Painful Biopsies For Myeloma Patients: MIT Research

April 15, 2017 Vijay Soni 0

No More Painful Biopsies For Myeloma Patients: MIT Research By: Jennifer Chu | MIT News Office April 15, 2017 Multiple myeloma is a cancer of the plasma cells, which are white blood cells produced in bone marrow that churn out antibodies to help fight infection. When plasma cells become cancerous, [..]

FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Multiple Sclerosis

April 4, 2017 Vijay Soni 0

FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Multiple Sclerosis An important new treatment option for people with relapsing forms of multiple sclerosis (RMS) demonstrating superior efficacy on the three major markers of disease activity compared with Rebif® A favorable benefit-risk profile demonstrated in three large Phase III studies with a diverse [..]